New guidelines for treating rheumatoid arthritis

Jul 22, 2008

Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB).

Lead author Kenneth Saag, M.D., M.Sc., a professor in the UAB Division of Clinical Immunology and Rheumatology, said the new guidelines update strategies for treating RA with the goal of preventing joint damage and disability.

The new recommendations do not strive to replace individualized medical decisions, Saag said. Instead, they are meant to guide rheumatologists and other health care workers toward the most updated recommendations. The last set of American College of Rheumatology RA treatment guidelines was published in 2002.

"The recommendations developed are not intended to be used in a 'cookbook' or prescriptive manner, or to limit a physician's clinical judgment," Saag said. "They provide guidance based on clinical evidence and expert panel input."

The recommendations focus on several classes of anti-arthritic drugs, including a potent group of agents called disease-modifying anti-rheumatic drugs (DMARDs). Newer genetically engineered DMARDs called biologics often work in combination with earlier therapies. Many anti-arthritic drugs are designed to stop damaging inflammation, and biologics work to interrupt the chain of events that leads to inflammation.

Newer biologics called anti-TNF agents – adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade) – prevent the production of an immunity protein that plays a role in inflammation.

Some of the key recommendations include:

-- Methotrexate or leflunomide therapy is recommended for most RA patients.
-- Anti-TNF agents etanercept, infliximab, or adalimumab along with methotrexate can be used in new or early RA cases with worsening and severe symptoms.
-- Doctors should not initiate or resume treatment with methotrexate, leflunomide, or biologics if RA patients have active bacterial infection, shingles (herpes-zoster), hepatitis B, hepatitis C and active or latent tuberculosis.
-- Doctors should not prescribe anti-TNF agents to patients with a history of heart failure, lymphoma or multiple sclerosis.

Source: University of Alabama at Birmingham

Explore further: Nigeria expected to be declared Ebola-free

add to favorites email to friend print save as pdf

Related Stories

Body by smartphone

Jul 30, 2014

We love our smartphones. Since they marched out of the corporate world and into the hands of consumers about 10 years ago, we've relied more and more on our iPhone and Android devices to organize our schedules, ...

Recommended for you

EU seeking to create $1.27 billion Ebola fund

8 minutes ago

European Union nations are working to reach 1 billion euros ($1.27 billion) in aid by the end of the week to fight Ebola in West Africa and are seeking a common approach to the crisis.

Panic over Ebola echoes the 19th-century fear of cholera

10 minutes ago

On October 19 an inspector sent north from London to Sunderland reported a long-awaited arrival: the first British case of cholera. It was 1831 and as part of a second pandemic cholera had again progressed ...

EU tackles Ebola response

3 hours ago

European Union foreign ministers thrashed out measures to help halt Ebola's deadly spread on Monday, as Nigeria—Africa's most populous country—was expected to be declared free of the disease.

WHO declares Nigeria Ebola-free (Update)

3 hours ago

Africa's most populous nation Nigeria was on Monday declared officially Ebola free but warned that it remained vulnerable as long as the virus was raging elsewhere in west Africa.

User comments : 0